BLLN
BLLN clinical trials: BillionToOne, Inc.
Every trial on ClinicalTrials.gov where BillionToOne, Inc. is the lead sponsor or a listed collaborator, the trials it leads first, each labelled Lead or Collaborator. Phase, status and dates as registered.
- 3
- Trials linked
- 1
- As lead sponsor
- 2
- As collaborator
- 0
- Primary completions as lead sponsor, next 90 days
BLLN on the catalyst calendar · BLLN registry changes
| Primary completion | Trial | Company and role | Phase | Status | Enrollment | Interventions | Completion |
|---|---|---|---|---|---|---|---|
| Dec 2027Sponsor estimate | NCT07643896The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study...BillionToOne Inc. · Pregnant Individuals | BLLNLead | No phase registered | Recruiting | Locked | Locked | Locked |
| Sep 30, 2030Sponsor estimate | NCT07096362Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal AdenocarcinomaUniversity of Miami · Metastatic Pancreatic Ductal Adenocarcinoma | BLLNCollaborator | Phase 2 | Recruiting | Locked | Locked | Locked |
| Jun 2027Sponsor estimate | NCT05733689Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)University of California, Irvine · Gastroesophageal Adenocarcinoma | BLLNCollaborator | Phase 1 | Recruiting | Locked | Locked | Locked |
- Primary completion Dec 2027Sponsor estimateNo phase registeredNCT07643896The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study...BillionToOne Inc. · Pregnant IndividualsRecruitingBLLNLead
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Sep 30, 2030Sponsor estimatePhase 2NCT07096362Utility of ctDNA in Early Switch of First-line Chemotherapy in Metastatic Pancreatic Ductal AdenocarcinomaUniversity of Miami · Metastatic Pancreatic Ductal AdenocarcinomaRecruitingBLLNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
- Primary completion Jun 2027Sponsor estimatePhase 1NCT05733689Response Adapted Neoadjuvant Therapy in Gastroesophageal Cancers (RANT-GC Trial)University of California, Irvine · Gastroesophageal AdenocarcinomaRecruitingBLLNCollaborator
- Enrollment
- Locked
- Completion
- Locked
- Interventions
- Locked
Enrollment, interventions and the start and completion dates are locked on 3 rows here. Included with TrialScanner ($9.99 a month) and Signal8 Pro.
Unlock with TrialScanner